comparemela.com

Cardona Portela News Today : Breaking News, Live Updates & Top Stories | Vimarsana

JAMA Neurology publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for ischemic stroke

The results from APRIL study, previously presented at the International Stroke Conference 2023, indicate that ApTOLL showed good safety in 151 acute ischemic stroke patients.The article also highlights that the preliminary efficacy results show that ApTOLL significantly reduces mortality and long-term functional dis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.